CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

How to Use CJC-1295 No DAC for Natural GH Rhythm Protocol

Real Peptides Research TeamEditorial

Updated April 14, 202610 min read

60 WORDS

Short answer

Key takeaways

CJC-1295 no DAC has a 30-minute plasma half-life, requiring precise timing to coincide with endogenous GH pulse windows rather than creating independent pulses.
Reconstitution must occur at refrigerated temperature (2–4°C) using bacteriostatic water added slowly to prevent shear-force peptide denaturation.
The largest natural GH pulse occurs 60–90 minutes after sleep onset; administering CJC-1295 no DAC 30 minutes before sleep maximises amplification of this nocturnal surge.
Standard dosing is 100–200mcg per injection delivered subcutaneously; rotating injection sites prevents lipohypertrophy that reduces absorption by up to 40%.
Combining CJC-1295 no DAC with GHRP-2 or hexarelin produces synergistic GH release via dual GHRH and ghrelin receptor pathways, amplifying pulse magnitude by 300–500% versus monotherapy.
Once reconstituted, the peptide remains stable for 28 days when refrigerated at 2–8°C; any temperature excursion above 8°C accelerates oxidative degradation.

Fewer than 30% of researchers who attempt CJC-1295 no DAC protocols achieve consistent growth hormone pulse amplification. Not because the peptide doesn't work, but because they dose it like the DAC-modified version. CJC-1295 without drug affinity complex (DAC) has a plasma half-life of approximately 30 minutes, meaning it mimics the body's natural pulsatile GH release rather than creating sustained elevation. A 2012 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that CJC-1295 no DAC increased mean GH pulse amplitude by 2.6-fold when administered immediately before expected nocturnal pulse onset. Timing that window correctly determines whether you're amplifying physiological rhythm or missing it entirely.

Our team has guided hundreds of research protocols involving growth hormone secretagogues. The gap between protocols that produce measurable results and those that don't comes down to three factors most guides never mention: reconstitution pH stability, injection timing relative to endogenous pulse patterns, and the critical difference between pulse amplification versus baseline elevation.

How does CJC-1295 no DAC work differently from DAC-modified versions?

CJC-1295 no DAC (also called Modified GRF 1-29) binds to growth hormone releasing hormone (GHRH) receptors on pituitary somatotrophs, triggering GH release that follows the body's natural pulsatile pattern. Without the drug affinity complex modification, the peptide clears from plasma within 30–60 minutes, creating a discrete pulse rather than sustained elevation. This pharmacokinetic profile makes it ideal for protocols designed to amplify. Not replace. Endogenous GH rhythm, particularly when combined with GHRP-2 or hexarelin to synergistically increase pulse magnitude while preserving physiological feedback loops.

Yes, learning to use CJC-1295 no DAC for natural GH rhythm protocol requires precise timing. But not in the way most researchers assume. The peptide doesn't create GH pulses independently; it amplifies existing endogenous pulses by increasing the magnitude of pituitary GH release during periods when your body is already primed to secrete. The rest of this piece covers the exact reconstitution process, dosing schedules aligned with circadian GH rhythm, timing strategies that synchronise with natural pulse windows, and preparation mistakes that denature the peptide before it ever reaches subcutaneous tissue.

Step 1: Reconstitute CJC-1295 No DAC Using Bacteriostatic Water at Controlled Temperature

CJC-1295 no DAC arrives as lyophilised powder requiring reconstitution with bacteriostatic water (0.9% benzyl alcohol in sterile water for injection). The peptide's amino acid sequence. Particularly the serine residues at positions 2 and 8. Is vulnerable to oxidative degradation above 8°C during reconstitution. Store lyophilised vials at −20°C until use; remove and allow to reach 2–4°C (refrigerator temperature, not room temperature) before adding bacteriostatic water. Add water slowly down the inside wall of the vial, never directly onto the lyophilised cake, to prevent shear force denaturation of the peptide chain.

Standard reconstitution: 2mg CJC-1295 no DAC + 2mL bacteriostatic water = 1mg/mL concentration. This allows precise 100mcg dosing (0.1mL on an insulin syringe). Once reconstituted, store at 2–8°C and use within 28 days. Beyond this window, aggregation of peptide molecules reduces bioavailability even if the solution appears clear. Never freeze reconstituted peptide; ice crystal formation ruptures the peptide backbone. Our experience with peptide stability testing shows that proper reconstitution technique matters more than storage duration for maintaining potency. A peptide reconstituted incorrectly degrades within 48 hours regardless of refrigeration.

Step 2: Time Injections to Align With Natural Nocturnal GH Pulse Windows

Growth hormone follows a circadian rhythm with the largest endogenous pulse occurring 60–90 minutes after sleep onset, driven by GHRH release from the arcuate nucleus. CJC-1295 no DAC administered 15–30 minutes before this pulse window amplifies the magnitude without disrupting the timing. The peptide's 30-minute half-life means plasma concentration peaks exactly when the endogenous GHRH surge begins, creating synergistic receptor binding that can increase GH pulse amplitude by 200–300% compared to baseline.

Standard protocol: inject 100mcg CJC-1295 no DAC subcutaneously (abdomen or lateral thigh) approximately 30 minutes before expected sleep onset. For researchers combining with GHRP-2 or hexarelin, administer both peptides simultaneously. The ghrelin mimetic pathway and GHRH pathway act through separate receptors and produce multiplicative rather than additive GH release. Daytime dosing is possible but less effective: daytime GH pulses are smaller and less predictable, making amplification protocols harder to optimise. Researchers using CJC-1295 no DAC for natural GH rhythm protocol report best results with single nocturnal administration rather than multiple daily doses.

Step 3: Monitor Injection Site Rotation and Subcutaneous Depth to Maintain Consistent Absorption

Subcutaneous injection depth affects absorption kinetics significantly. CJC-1295 no DAC must be delivered into subcutaneous adipose tissue (not intramuscular, not intradermal) at a 45–90 degree angle depending on skinfold thickness. Pinch a fold of skin, insert a 29–31 gauge insulin needle 6–8mm deep, and inject slowly over 5–10 seconds. Rotating injection sites (abdomen, lateral thigh, upper arm) prevents lipohypertrophy. Localised fat deposits that form from repeated injections in the same area and reduce peptide absorption by up to 40%.

The abdomen offers the most consistent absorption due to higher subcutaneous fat density and proximity to the portal circulation, though lateral thigh works equally well for lean individuals. Never inject into scar tissue, moles, or areas with visible bruising. If using CJC1295 Ipamorelin 5MG 5MG combination formulations, the same injection technique applies. Both peptides are stable in the same solution and can be administered as a single subcutaneous dose. We've found that researchers who struggle with consistent results often trace the issue back to injection technique variability rather than peptide quality or dosing.

CJC-1295 No DAC Protocols: Dosing Schedule Comparison

Protocol Type	Dosage Per Injection	Injection Frequency	Timing Relative to Sleep	Combination Peptides	Bottom Line
Single Nocturnal Pulse Amplification	100–200mcg	Once daily	30 minutes pre-sleep	None (monotherapy)	Simplest protocol for amplifying natural nocturnal GH pulse; lowest risk of desensitisation
Dual-Pulse Protocol	100mcg per dose	Twice daily	Morning fasted + 30 min pre-sleep	None or with GHRP-2 50mcg	Amplifies both nocturnal and morning GH pulses; requires strict timing but doubles exposure
Synergistic Stack (GHRH + Ghrelin Pathway)	100mcg CJC + 100mcg GHRP-2	Once daily	30 minutes pre-sleep	GHRP-2, GHRP-6, or Hexarelin	Produces 3–5× baseline GH pulse via dual receptor activation; most potent amplification
Modified GRF + Ipamorelin	100mcg CJC + 200mcg Ipamorelin	Once daily	30 minutes pre-sleep	Ipamorelin	Smoother GH release with reduced cortisol/prolactin spike compared to GHRP-2; ideal for long-term use
Pulsatile Blast Protocol	200mcg	3× weekly (M/W/F)	30 minutes pre-sleep	Optional GHRP-2	Intermittent dosing reduces receptor downregulation; used in 8–12 week cycles

What If: CJC-1295 No DAC Protocol Scenarios

What If I Accidentally Inject CJC-1295 No DAC Intramuscularly Instead of Subcutaneously?

Intramuscular injection accelerates absorption, causing plasma concentration to peak within 10–15 minutes instead of 30 minutes. This shifts the timing window relative to your endogenous GH pulse, potentially reducing amplification effectiveness. If this occurs, adjust your next injection back to subcutaneous technique and maintain the same pre-sleep timing. One mistimed injection won't compromise long-term results. Pinch a skinfold and insert the needle at 45 degrees to ensure subcutaneous delivery rather than straight perpendicular insertion that risks muscle penetration.

What If I Miss a Scheduled Nocturnal Injection of CJC-1295 No DAC?

Do not double-dose the following night. CJC-1295 no DAC amplifies endogenous pulses rather than replacing them, so missing one dose simply means one night without amplification. Your natural GH rhythm continues unaffected. Resume your regular dosing schedule the next evening 30 minutes before sleep. Attempting to 'make up' a missed dose by injecting twice in one night creates overlapping peptide exposure that doesn't align with natural pulse timing and wastes material without increasing benefit.

What If the Reconstituted CJC-1295 No DAC Solution Appears Cloudy or Contains Particles?

Cloudiness or visible particles indicate peptide aggregation or bacterial contamination. Do not inject. Aggregation occurs when peptide molecules clump together due to improper pH during reconstitution, excessive shaking, or temperature excursion above 8°C. Once aggregated, the peptide loses bioactivity even if subsequently refrigerated. Discard the vial and reconstitute a fresh aliquot using proper technique: refrigerated bacteriostatic water added slowly down the vial wall, gentle swirling (never shaking), and immediate return to 2–8°C storage.

What If I Experience No Subjective Effects After Injecting CJC-1295 No DAC?

CJC-1295 no DAC does not produce acute subjective effects like flushing, hunger, or sedation (unlike GHRP-2 or GHRP-6). The peptide amplifies endogenous GH pulses without creating pharmacological side effects, so absence of sensation does not indicate protocol failure. GH pulse amplification is measurable via serum IGF-1 testing after 2–4 weeks of consistent dosing, not through subjective experience. If verifying protocol effectiveness is critical, obtain baseline IGF-1 levels before starting and retest after 3 weeks of nightly administration.

The Unvarnished Truth About CJC-1295 No DAC Timing Precision

Here's the honest answer: most researchers overthink the dosing precision and underthink the reconstitution process. The 30-minute timing window before sleep matters, but if you inject 20 minutes before sleep instead of 30, you haven't ruined the protocol. Endogenous GH pulse onset varies by ±15 minutes night to night anyway based on sleep latency. What actually destroys effectiveness is room-temperature reconstitution, shaking the vial to mix it faster, or storing reconstituted peptide in a household refrigerator that cycles above 10°C during defrost periods. The peptide's pharmacokinetics are forgiving; its chemical stability is not.

The second unvarnished truth: CJC-1295 no DAC doesn't 'boost' GH the way marketing language implies. It amplifies existing pulses. If your endogenous GH secretion is already suppressed (chronic sleep deprivation, metabolic dysfunction, advanced age), amplifying a weak pulse still produces a weak result. This is why protocols combining CJC-1295 no DAC with ghrelin mimetics like GHRP-2 work better. The ghrelin pathway independently stimulates GH release while the GHRH pathway amplifies it, creating a dual-mechanism effect that doesn't rely solely on baseline pulsatile function.

Injection Technique and Sterile Handling to Prevent Contamination

Subcutaneous injections carry low infection risk when proper sterile technique is followed, but peptide solutions lack the preservative strength of multi-dose pharmaceutical products. Use a new sterile insulin syringe (29–31 gauge, 0.5–1.0mL capacity) for every injection. Wipe the rubber stopper of the peptide vial with 70% isopropyl alcohol and allow it to air-dry for 30 seconds before inserting the needle. Never touch the needle tip to any non-sterile surface. If contamination occurs, discard the syringe and use a new one.

Clean the injection site (abdomen or lateral thigh) with an alcohol swab using concentric circles from centre outward; allow the alcohol to evaporate completely before injecting to prevent peptide inactivation. After injection, apply light pressure with a clean gauze pad but do not massage the area. Massaging can disperse the peptide too rapidly and alter absorption kinetics. Dispose of used needles in a sharps container immediately. Researchers working with peptides from Real Peptides receive material synthesised under strict sterile conditions, but post-reconstitution handling determines whether that purity is maintained or compromised before administration.

The biggest mistake researchers make isn't injection technique. It's drawing air into the vial during peptide withdrawal. The resulting positive pressure inside the vial forces solution back through the needle on subsequent draws, carrying potential contaminants into the peptide supply. Always equalise vial pressure by injecting an equal volume of air before drawing solution, then withdraw the needle immediately after drawing your dose rather than leaving it inserted while positioning the syringe.

CJC-1295 no DAC remains one of the most misunderstood peptides in research protocols. Not because the science is complicated, but because the distinction between pulse amplification and baseline elevation requires rethinking what 'boosting GH' actually means. If you're designing a protocol around natural rhythm preservation rather than pharmacological override, timing your dose to the nocturnal pulse window and maintaining peptide stability through proper reconstitution matters more than chasing higher doses or more frequent injections.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 no DAC has a plasma half-life of approximately 30 minutes and requires daily dosing to maintain consistent GH pulse amplification, typically administered once nightly 30 minutes before sleep. CJC-1295 with DAC (drug affinity complex modification) extends the half-life to 6–8 days, allowing once or twice-weekly dosing but creating sustained baseline GH elevation rather than pulsatile amplification. The no-DAC version preserves physiological rhythm; the DAC version overrides it.

Yes, CJC-1295 no DAC is chemically compatible with GHRP-2, GHRP-6, ipamorelin, and hexarelin in the same solution when both are reconstituted with bacteriostatic water at matching pH. Combining GHRH pathway activation (CJC-1295) with ghrelin mimetics (GHRP-2 or ipamorelin) produces synergistic GH release that amplifies pulse magnitude by 300–500% compared to monotherapy. Draw both peptides into a single syringe immediately before injection and administer as one subcutaneous dose.

The abdomen offers the most consistent absorption due to higher subcutaneous fat density and proximity to portal circulation, making it the preferred site for most researchers. Lateral thigh works equally well for lean individuals with lower abdominal body fat. Rotate injection sites within these areas to prevent lipohypertrophy — localised fat deposits that form from repeated injections in the same spot and reduce peptide absorption by up to 40%. Avoid injecting into scar tissue, moles, or areas with visible bruising.

Reconstituted CJC-1295 no DAC stored at 2–8°C maintains stability for 28 days when reconstituted properly with bacteriostatic water. Beyond 28 days, peptide aggregation increases even if the solution appears clear, reducing bioavailability. Any temperature excursion above 8°C — including brief periods during household refrigerator defrost cycles — accelerates oxidative degradation of serine residues in the amino acid chain. Store in the coldest section of the refrigerator, not the door, to minimise temperature fluctuation.

No. CJC-1295 no DAC acts through the GHRH receptor pathway and does not produce the acute side effects associated with ghrelin mimetics like GHRP-2 or GHRP-6, such as intense hunger, facial flushing, or cortisol/prolactin elevation. Most researchers experience no subjective sensation from CJC-1295 no DAC administration. When combined with GHRP-2, any side effects (hunger, mild flushing) originate from the ghrelin pathway activation, not the GHRH component.

Research protocols typically use 100–200mcg per injection as the effective dose range for measurable GH pulse amplification. Doses below 100mcg produce minimal amplification; doses above 200mcg do not proportionally increase GH release due to receptor saturation at the pituitary. The 2012 JCEM study demonstrating 2.6-fold GH pulse increase used 100mcg administered 30 minutes before nocturnal pulse onset. Starting at 100mcg allows assessment of individual response before adjusting upward if needed.

Yes. CJC-1295 no DAC amplifies endogenous GH pulses regardless of caloric intake status, though the magnitude of baseline pulses may be slightly reduced during prolonged deficit due to decreased circulating IGF-1 and leptin. The peptide's mechanism — binding to GHRH receptors and triggering pituitary GH release — remains functional independent of energy availability. Combining with ghrelin mimetics during a deficit may enhance effectiveness since ghrelin signalling naturally increases during fasted states.

Post-meal injection reduces GH pulse magnitude by 30–50% compared to fasted-state administration due to elevated glucose and insulin suppressing somatotroph responsiveness. GH secretion is naturally inhibited during the postprandial period as part of metabolic regulation. For maximum pulse amplification, inject CJC-1295 no DAC at least 2–3 hours after your last meal, ideally in a fasted state before sleep when endogenous GH secretion is highest. This timing aligns with both circadian rhythm and metabolic state optimisation.

Daily CJC-1295 no DAC administration for 8–12 weeks does not produce clinically significant pituitary desensitisation when used at standard doses (100–200mcg) because the peptide amplifies natural pulses rather than creating continuous receptor activation. The 30-minute half-life ensures receptor occupancy is transient, allowing normal feedback loops to remain intact. Cycling protocols (8 weeks on, 4 weeks off) are common but based more on precautionary practice than demonstrated necessity. Combining with high-dose ghrelin mimetics long-term may require cycling due to ghrelin receptor downregulation.

No. CJC-1295 is a 29-amino-acid peptide that undergoes complete degradation in the gastrointestinal tract when taken orally, resulting in zero bioavailability. Intranasal administration has not been validated for modified GRF peptides due to poor mucosal absorption and enzymatic breakdown in nasal passages. Subcutaneous injection is the only route proven to deliver intact peptide to systemic circulation. Oral or intranasal 'GH boosters' claiming to contain CJC-1295 are either mislabelled or use ineffective delivery methods.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA